Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
24 Juin 2024 - 7:00AM
UK Regulatory
Roche launches new analytical units for cobas® pro integrated
solutions delivering greater efficiency and capacity to
laboratories
- The cobas® c 703 and cobas®
ISE neo analytical units, deliver higher testing capacity and
increased automation helping to improve laboratory workflows and
advance patient care.
- The new cobas c 703
analytical unit offers industry-leading high throughput clinical
chemistry testing1
with up to 2,000 tests per hour and 70 reagent positions,
doubling the existing clinical chemistry throughput on cobas pro
integrated solutions.
- The new cobas ISE neo
analytical unit delivers more efficient ISE testing, reducing
hands-on time through automated maintenance.
Basel, 24 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced today the launch of its new analytical units, cobas® c
703 and cobas® ISE neo, for the cobas® pro integrated solutions, in
countries accepting the CE mark. The cobas pro integrated solutions
is a scalable and modular diagnostic platform designed for
high-volume laboratories. The cobas c 703 and cobas ISE neo
analytical units offer cutting-edge features to help address some
of the key challenges faced by diagnostic laboratories worldwide
such as shortage of qualified staff and space limitations.
“Today more than ever, accurate and timely diagnostics is
critical for effective delivery of healthcare. Labs are under
increasing pressure to process more samples, at greater speed
without compromising on accuracy,” said Matt Sause, CEO of Roche
Diagnostics.“With the launch of the cobas c 703 and cobas ISE neo,
we are taking our latest generation clinical chemistry and
immunochemistry platform, the cobas pro integrated solutions, to
the next level. By integrating high-volume clinical chemistry
testing and increased automation, we will set a new standard for
high volume testing in the clinical lab.”
cobas c 703 analytical unit
The new cobas c 703 analytical unit is designed to double the
clinical chemistry throughput on cobas pro integrated solutions,
offering up to 2,000 tests per hour and 70 reagent positions. This
increased onboard reagent capacity means more high-value tests can
be performed whilst improving workflow efficiency and saving time
spent reloading reagents. This new unit will minimise operator
maintenance to once a month, increasing uptime for
laboratories.
cobas ISE neo analytical unit
The cobas ISE neo is designed to improve ion selective electrode
(ISE) testing efficiency, offering up to 1,800 tests per hour. With
a number of innovative hardware and software features, including an
automated calibration concept, it significantly reduces the need
for manual intervention. It also performs more tests per reagent
bottle, reducing the frequency of bottle changes, minimising
plastic waste, and reducing logistical efforts compared to previous
generation systems.
By automating work that would have been done manually in the
past, these new units further improve lab efficiency, thus
addressing the shortage of qualified staff and increasing the
volume of tests that can be delivered to the people who need them
most.
About cobas pro integrated solutions
Launched in 2018, cobas pro integrated solutions is a scalable and
modular solution designed to meet mid-to-very-high volume clinical
chemistry and immunochemistry testing needs. It aims to increase
efficiency with fast analytical units, intelligent sample routing,
and short assay incubation times, with 93% of Roche immunoassays
having reaction times of 18 minutes or less.2 This
analyser features automated maintenance and cobas® AutoCal, an
automated calibration procedure, to save hands-on time.
Additionally, it incorporates cobas® SonicWash, an ultrasonic probe
cleaning to ensure sample integrity.
cobas pro integrated solutions provides fully standardised
results and operation to cobas® pure integrated solutions.
Together, they deliver a seamless experience and the highest level
of standardisation using the same reagents and assay menu,
delivering consistent results and operation, and therefore allowing
for flexible staff assignment and minimal training needs. This also
makes the systems ideal candidates for integrated health networks
and lab chains.
cobas pro integrated solutions is fully compatible with the
cobas® mobile solution, a tablet that integrates multiple Roche
applications, allowing laboratory professionals to interact with
the analyser from anywhere in the lab.
With cobas pro integrated solutions, the required sample volume
per test has been reduced on average by 43% compared to previous
generation systems.3 Additionally, the plastic generated
per test result has been reduced by up to 78% due to smaller
reagent pack sizes and a higher number of tests per
pack.4
Designed to seamlessly integrate into clinical chemistry and
immunochemistry testing, Roche’s innovative mass spectrometry
analyser will also be available as part of the cobas pro integrated
solutions in the near future.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first
industrial manufacturers of branded medicines, Roche has grown into
the world’s largest biotechnology company and the global leader in
in-vitro diagnostics. The company pursues scientific excellence to
discover and develop medicines and diagnostics for improving and
saving the lives of people around the world. We are a pioneer in
personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide
the best care for each person we partner with many stakeholders and
combine our strengths in Diagnostics and Pharma with data insights
from the clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the fifteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
References
[1] Internal data on file
[2] Roche cobas e 801 Immunochemistry Assay Method Sheets
[3] Reduction is a comparison to cobas c 501 module, part of cobas®
6000 analyser series
[4] Reduction is a comparison to cobas e 601 module, part of cobas®
6000 analyser series
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58
|
Sileia
Urech
Phone: +41 79 935 81 48
|
Nathalie
Altermatt
Phone: +41 79 771 05 25
|
Simon
Goldsborough
Phone: +44 797 32 72 915
|
Karsten
Kleine
Phone: +41 79 461 86 83
|
Nina
Mählitz
Phone: +41 79 327 54 74 |
Kirti
Pandey
Phone: +49 172 6367262
|
Yvette
Petillon
Phone: +41 79 961 92 50 |
Dr.
Rebekka Schnell
Phone: +41 79 205 27 03 |
|
Roche Investor Relations
Dr. Bruno
Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
|
Dr.
Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
|
Dr.
Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com |
|
Investor Relations North America
Loren
Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
|
- 24062024_MR_cobas pro integrated solutions_en
Roche (LSE:0QQ6)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Roche (LSE:0QQ6)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024